Inhaled Corticosteroids and Endocrine Effects in Childhood

• Autores: David B. Allen
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 49, Nº. 4, 2020 (Ejemplar dedicado a: Pediatric Endocrinology), págs. 651-665
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Asthma is the most common chronic inflammatory disease of children, and inhaled corticosteroids (ICSs) are the most effective and commonly used treatment of persistent asthma. ICSs currently approved for and commonly used by children with asthma include beclomethasone dipropionate, budesonide, fluticasone propionate, mometasone furoate, ciclesonide, and triamcinolone acetonide. This article reviews 4 areas critical to understanding potential adverse endocrine outcomes of ICSs and placing them in proper perspective: (1) influence of drug/delivery device properties on systemic steroid burden; (2) adrenal insufficiency during ICS treatment; (3) growth effects of ICS and asthma itself; and (4) bone mineral accretion during ICS therapy.